Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2002 1
2003 2
2006 1
2007 1
2009 10
2010 18
2011 1
2012 1
2014 1
2015 2
2017 1
2018 1
2019 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

37 results
Results by year
Filters applied: . Clear all
Page 1
Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.
Hatlen MA, Schmidt-Kittler O, Sherwin CA, Rozsahegyi E, Rubin N, Sheets MP, Kim JL, Miduturu C, Bifulco N, Brooijmans N, Shi H, Guzi T, Boral A, Lengauer C, Dorsch M, Kim RD, Kang YK, Wolf BB, Hoeflich KP. Hatlen MA, et al. Among authors: brooijmans n. Cancer Discov. 2019 Dec;9(12):1686-1695. doi: 10.1158/2159-8290.CD-19-0367. Epub 2019 Oct 1. Cancer Discov. 2019. PMID: 31575540 Free article.
A precision therapy against cancers driven by KIT/PDGFRA mutations.
Evans EK, Gardino AK, Kim JL, Hodous BL, Shutes A, Davis A, Zhu XJ, Schmidt-Kittler O, Wilson D, Wilson K, DiPietro L, Zhang Y, Brooijmans N, LaBranche TP, Wozniak A, Gebreyohannes YK, Schöffski P, Heinrich MC, DeAngelo DJ, Miller S, Wolf B, Kohl N, Guzi T, Lydon N, Boral A, Lengauer C. Evans EK, et al. Among authors: brooijmans n. Sci Transl Med. 2017 Nov 1;9(414):eaao1690. doi: 10.1126/scitranslmed.aao1690. Sci Transl Med. 2017. PMID: 29093181 Clinical Trial.
First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway.
Hagel M, Miduturu C, Sheets M, Rubin N, Weng W, Stransky N, Bifulco N, Kim JL, Hodous B, Brooijmans N, Shutes A, Winter C, Lengauer C, Kohl NE, Guzi T. Hagel M, et al. Among authors: brooijmans n. Cancer Discov. 2015 Apr;5(4):424-37. doi: 10.1158/2159-8290.CD-14-1029. Epub 2015 Mar 16. Cancer Discov. 2015. PMID: 25776529 Free article.
Targeting kinases with precision.
Gardino AK, Evans EK, Kim JL, Brooijmans N, Hodous BL, Wolf B, Lengauer C. Gardino AK, et al. Among authors: brooijmans n. Mol Cell Oncol. 2018 Apr 11;5(3):e1435183. doi: 10.1080/23723556.2018.1435183. eCollection 2018. Mol Cell Oncol. 2018. PMID: 30250891 Free PMC article.
Structure-based optimization of PKCtheta inhibitors.
Mosyak L, Xu Z, Joseph-McCarthy D, Brooijmans N, Somers W, Chaudhary D. Mosyak L, et al. Among authors: brooijmans n. Biochem Soc Trans. 2007 Nov;35(Pt 5):1027-31. doi: 10.1042/BST0351027. Biochem Soc Trans. 2007. PMID: 17956269 Review.
Molecular recognition and docking algorithms.
Brooijmans N, Kuntz ID. Brooijmans N, et al. Annu Rev Biophys Biomol Struct. 2003;32:335-73. doi: 10.1146/annurev.biophys.32.110601.142532. Epub 2003 Jan 28. Annu Rev Biophys Biomol Struct. 2003. PMID: 12574069 Review.
A structural informatics approach to mine kinase knowledge bases.
Brooijmans N, Mobilio D, Walker G, Nilakantan R, Denny RA, Feyfant E, Diller D, Bikker J, Humblet C. Brooijmans N, et al. Drug Discov Today. 2010 Mar;15(5-6):203-9. doi: 10.1016/j.drudis.2009.11.005. Epub 2009 Dec 3. Drug Discov Today. 2010. PMID: 19948242 Review.
Stability of macromolecular complexes.
Brooijmans N, Sharp KA, Kuntz ID. Brooijmans N, et al. Proteins. 2002 Sep 1;48(4):645-53. doi: 10.1002/prot.10139. Proteins. 2002. PMID: 12211032
Identification of 2-oxatriazines as highly potent pan-PI3K/mTOR dual inhibitors.
Dehnhardt CM, Venkatesan AM, Chen Z, Delos-Santos E, Ayral-Kaloustian S, Brooijmans N, Yu K, Hollander I, Feldberg L, Lucas J, Mallon R. Dehnhardt CM, et al. Among authors: brooijmans n. Bioorg Med Chem Lett. 2011 Aug 15;21(16):4773-8. doi: 10.1016/j.bmcl.2011.06.063. Epub 2011 Jun 21. Bioorg Med Chem Lett. 2011. PMID: 21763134
37 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page